MANDEEP BAJAJ to Dipeptidyl-Peptidase IV Inhibitors
This is a "connection" page, showing publications MANDEEP BAJAJ has written about Dipeptidyl-Peptidase IV Inhibitors.
Connection Strength
1.026
-
DPP-4 inhibitors and atherosclerosis: the promise. Atherosclerosis. 2013 Apr; 227(2):224-5.
Score: 0.414
-
DPP-4 inhibition by linagliptin prevents cardiac dysfunction and inflammation by targeting the Nlrp3/ASC inflammasome. Basic Res Cardiol. 2019 08 06; 114(5):35.
Score: 0.163
-
Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 Diabetes. Cardiovasc Drugs Ther. 2018 04; 32(2):135-145.
Score: 0.149
-
SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor. Cardiovasc Drugs Ther. 2017 Apr; 31(2):119-132.
Score: 0.139
-
Potential of incretin-based therapies for non-alcoholic fatty liver disease. J Diabetes Complications. 2013 Jul-Aug; 27(4):401-6.
Score: 0.104
-
GLP-1 Receptor Agonists and Risk for Cirrhosis and Related Complications in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease. JAMA Intern Med. 2024 Nov 01; 184(11):1314-1323.
Score: 0.059